slcompose jto-jto jto-jto jto00308 jto0511-08a$sl
<zkeybdr;disk;js>
<XXjto003080511XX>
<<tt>>TABLE 1.
<mc>Clinicopathologic Features of non-BAC NSCLC Patients (N = 13,401) with UICC6 T4 and M Descriptors that Undergo Revisions as Proposed by IASLC
|
UICC6 stage IIIB |
UICC6 stage IV |
|||||
T4-“Additional nodules” (%) |
T4-“Pleural dissemination” (%) |
T4-“Pericardial effusion” (%) |
T4-“invasion” (%) |
M-“Ipsilateral pulmonary nodules” (%) |
M-“Contralateal pulmonary nodules” (%) |
M- “distant metastasis” (%) |
|
N |
422 |
1773 |
320 |
1607 |
745 |
1148 |
6886 |
Mean age of diagnosis |
67.9 |
69.6 |
66.1 |
66.0 |
67.4 |
68.6 |
65.1 |
([plusmn]SD) |
[plusmn]10.3 |
[plusmn]11.5 |
[plusmn]12.3 |
[plusmn]11.0 |
[plusmn]10.4 |
[plusmn]11.3 |
[plusmn]11.3 |
Gender |
|||||||
<ems>Male |
228 (54.0) |
1033 (58.2) |
168 (52.5) |
952 (59.2) |
404 (54.2) |
627 (54.6) |
3975 (57.7) |
<ems>Female |
194 (46.0) |
740 (41.7) |
152 (45.7) |
655 (40.8) |
341 (45.8) |
521 (45.4) |
2911 (42.3) |
Race |
|||||||
<ems>Caucasian |
336 (79.6) |
1243 (70.1) |
231 (72.2) |
1153 (71.8) |
537 (72.1) |
819 (71.3) |
4888 (71.0) |
<ems>African-American |
31 (7.4) |
146 (8.2) |
22 (6.9) |
159 (9.9) |
67 (9.0) |
84 (7.3) |
630 (9.2) |
<ems>Hispanic |
26 (6.2) |
206 (11.6) |
36 (11.3) |
138 (8.6) |
77 (10.3) |
120 (10.5) |
703 (10.2) |
<ems>Chinese |
5 (1.2) |
50 (2.8) |
5 (1.6) |
32 (2.0) |
12 (1.6) |
31 (2.7) |
187 (2.7) |
<ems>Non-Chinese Asian |
23 (5.5) |
123 (6.9) |
23 (7.2) |
120 (7.5) |
51 (6.9) |
89 (7.6) |
451 (6.6) |
<ems>Other |
1 (0.2) |
5 (0.3) |
3 (0.9) |
5 (0.3) |
1 (0.1) |
5 (0.4) |
27 (0.4) |
Socioeconomic status (SES) |
|||||||
<ems>Quintile 1 (SES1-lowest) |
58 (13.7) |
339 (19.1) |
58 (18.1) |
242 (15.1) |
120 (16.1) |
177 (15.4) |
1074 (15.6) |
<ems>Quintile 2 (SES2) |
83 (19.7) |
383 (21.6) |
65 (20.3) |
318 (19.8) |
138 (18.5) |
245 (21.3) |
1327 (19.3) |
<ems>Quintile 3 (SES3) |
98 (23.2) |
390 (22.0) |
82 (25.6) |
378 (23.5) |
173 (23.2) |
254 (22.1) |
1505 (21.9) |
<ems>Quintile 4 (SES4) |
92 (21.8) |
360 (20.3) |
59 (18.4) |
345 (21.5) |
156 (20.9) |
241 (21.0) |
1542 (22.4) |
<ems>Quintile 5 (SES5-highest) |
91 (21.6) |
301 (17.0) |
56 (17.5) |
324 (20.2) |
158 (21.2) |
231 (20.1) |
1438 (20.9) |
Histology |
|||||||
<ems>Adenocarcinoma |
211 (50.0) |
692 (39.0) |
128 (40.0) |
528 (32.9) |
359 (48.2) |
487 (42.4) |
3173 (46.1) |
<ems>Squamous cell carcinoma |
97 (23.0) |
503 (28.4) |
85 (26.6) |
571 (35.5) |
196 (26.3) |
290 (25.3) |
1092 (15.9) |
<ems>Large Cell carcinoma |
19 (4.5) |
111 (6.3) |
25 (7.8) |
74 (4.6) |
28 (3.8) |
64 (5.6) |
440 (6.4) |
<ems>Undifferentiated carcinoma |
95 (22.5) |
467 (26.3) |
82 (25.6) |
434 (27.0) |
162 (21.7) |
307 (26.7) |
2181 (31.7) |
Histologic grade |
|||||||
<ems>Well-differentiated |
29 (6.9) |
49 (2.8) |
11 (3.4) |
37 (2.3) |
37 (5.0) |
48 (4.2) |
115 (1.7) |
<ems>Moderately-differentiated |
92 (21.8) |
254 (14.3) |
32 (10.0) |
264 (16.4) |
146 (19.6) |
184 (16.0) |
726 (10.5) |
<ems>Poorly-differentiated |
197 (46.7) |
733 (41.3) |
128 (40.0) |
715 (44.5) |
297 (39.9) |
405 (35.3) |
2436 (35.4) |
<ems>Un-differentiated |
13 (3.1) |
83 (4.7) |
21 (6.6) |
68 (4.2) |
30 (4.0) |
44 (3.8) |
321 (4.7) |
<ems>Unknown |
91 (21.6) |
654 (36.9) |
128 (40.0) |
523 (32.5) |
235 (31.5) |
467 (40.7) |
3288 (47.7) |
Surgery |
|||||||
<ems>Yes |
245 (58.1) |
124 (7.0) |
13 (4.1) |
366 (22.8) |
231 (31.0) |
89 (7.8) |
395 (5.7) |
<ems>No |
177 (41.9) |
1649 (93.0) |
307 (95.9) |
1241 (77.2) |
514 (69.0) |
1059 (92.2) |
6487 (94.2) |
<ems>Unknown |
0 (0.0) |
0. (0.0) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
4 (0.1) |
Radiation |
|||||||
<ems>Yes |
159 (37.7) |
660 (37.2) |
122 (38.1) |
1081 (67.3) |
266 (35.7) |
334 (29.1) |
3852 (55.9) |
<ems>No |
263 (62.3) |
1113 (62.8) |
198 (61.9) |
526 (32.7) |
479 (64.3) |
814 (70.9) |
3034 (44.1) |
Chemotherapy |
|||||||
<ems>Yes |
155 (36.7) |
711 (40.1) |
155 (48.4) |
960 (59.7) |
336 (45.1) |
549 (47.8) |
3141 (45.6) |
<ems>No |
261 (61.8) |
999 (56.3) |
154 (48.1) |
600 (37.3) |
387 (51.9) |
562 (49.0) |
3524 (51.2) |
Unknown |
6 (1.4) |
63 (3.6) |
11 (3.4) |
47 (2.9) |
22 (3.0) |
36 (3.1) |
221 (3.2) |
<<tabft>></.>
<<tt>>TABLE 2.
<mc>Survival Characteristics of non-BAC NSCLC Patients with the Seven Subtypes of UICC6 T4 and M Descriptors that Undergo Revisions as Proposed by IASLC
UICC6 T4 and M descriptors (IASLC proposed changes) |
Total |
Deaths |
1-yr survival estimate (%) |
5-yr survival estimate (%) |
Median overall survival (mo) |
T4-“additional nodules” (IASLC [rarrow] T3) |
422 |
250 |
64.0 |
22.6 |
20 |
T4-“invasion” (IASLC [rarrow] T4 [lsqb]no change[rsqb]) |
1607 |
1178 |
47.4 |
11.5 |
12 |
M-“ipsilateral intra-pulmonary nodules” (IASLC [rarrow] T4) |
745 |
555 |
46.2 |
9.5 |
11 |
M-“contralateral intra-pulmonary nodules” (IASLC [rarrow] M1a) |
1148 |
949 |
31.1 |
4.3 |
7 |
T4-“pleural dissemination” (IASLC [rarrow] M1a) |
1773 |
1557 |
22.7 |
3.9 |
5 |
T4-“pericardial effusion” (IASLC [rarrow] M1a) |
320 |
282 |
17.7 |
3.4 |
3 |
M-“distant metastasis” (IASLC [rarrow] M1b) |
6886 |
6252 |
18.3 |
1.3 |
4 |
<<tabft>></.>
<<tt>>TABLE 3.
<mc>Survival Characteristics of non-BAC NSCLC Patients with UICC6 T4 and M Descriptors that Undergo Revisions as Proposed by IASLC Stratified by Individual Histology
UICC6 T4 and M descriptors (IASLC proposed changes) |
Total |
Deaths |
1-yr survival estimate (%) |
5-yr survival estimate (%) |
Median OS (mo) |
Adenocarcinoma (N = 5578) |
|||||
<ems>T4-“additional nodules” (IASLC [rarrow] T3) |
211 |
117 |
70.0 |
25.4 |
22 |
<ems>T4-“invasion” (IASLC [rarrow] T4 [lsqb]no change[rsqb]) |
528 |
370 |
51.6 |
12.3 |
13 |
<ems>M-“ipsilateral intra-pulmonary nodules” (IASLC [rarrow] T4) |
359 |
254 |
54.3 |
12.6 |
15 |
<ems>M-“contralateral intra-pulmonary nodules” (IASLC [rarrow] M1a) |
487 |
390 |
35.6 |
6.3 |
8 |
<ems>T4-“pleural dissemination” (IASLC [rarrow] M1a) |
692 |
592 |
24.5 |
5.0 |
5 |
<ems>T4-“pericardial effusion” (IASLC [rarrow] M1a) |
128 |
116 |
14.4 |
3.0 |
3 |
<ems>M-“distant metastasis” (IASLC [rarrow] M1b) |
3173 |
2829 |
22.2 |
1.4 |
5 |
Squamous cell carcinoma (N = 2834) |
|||||
<ems>T4-“additional nodules” (IASLC [rarrow] T3) |
97 |
57 |
60.0 |
16.1 |
17 |
<ems>T4-“invasion” (IASLC [rarrow] T4 [lsqb]no change[rsqb]) |
571 |
432 |
45.8 |
9.7 |
11 |
<ems>M-“ipsilateral intra-pulmonary nodules” (IASLC [rarrow] T4) |
196 |
156 |
37.0 |
6.8 |
8 |
<ems>M-“contralateral intra-pulmonary nodules” (IASLC [rarrow] M1a) |
290 |
250 |
27.6 |
4.5 |
7 |
<ems>T4-“pleural dissemination” (IASLC [rarrow] M1a) |
503 |
435 |
24.3 |
3.6 |
5 |
<ems>T4-“pericardial effusion” (IASLC [rarrow] M1a) |
85 |
77 |
15.8 |
—a |
4 |
<ems>M-“distant metastasis” (IASLC [rarrow] M1b) |
1092 |
1024 |
14.7 |
1.8 |
4 |
Large cell carcinoma (N = 761) |
|||||
<ems>T4-“additional nodules” (IASLC [rarrow] T3) |
19 |
15 |
55.7 |
16.7 |
12 |
<ems>T4-“invasion” (IASLC [rarrow] T4 [lsqb]no change[rsqb]) |
74 |
60 |
42.8 |
9.3 |
9 |
<ems>M-“ipsilateral intra-pulmonary nodules” (IASLC [rarrow] T4) |
28 |
19 |
33.8 |
16.9 |
7.5 |
<ems>M-“contralateral intra-pulmonary nodules” (IASLC [rarrow] M1a) |
64 |
57 |
28.2 |
2.4 |
7 |
<ems>T4-“pleural dissemination” (IASLC [rarrow] M1a) |
111 |
105 |
14.5 |
3.1 |
3 |
<ems>T4-“pericardial effusion” (IASLC [rarrow] M1a) |
25 |
20 |
22.3 |
—a |
5 |
<ems>M-“distant metastasis” (IASLC [rarrow] M1b) |
440 |
414 |
10.6 |
1.3 |
3 |
Undifferentiated carcinoma (N = 3728) |
|||||
<ems>T4-“additional nodules” (IASLC [rarrow] T3) |
95 |
61 |
58.6 |
15.2 |
16 |
<ems>T4-“invasion” (IASLC [rarrow] T4 [lsqb]no change[rsqb]) |
434 |
316 |
45.0 |
15.3 |
11 |
<ems>M-“ipsilateral intra-pulmonary nodules” (IASLC [rarrow] T4) |
162 |
126 |
40.7 |
5.7 |
10 |
<ems>M-“contralateral intra-pulmonary nodules” (IASLC [rarrow] M1a) |
307 |
252 |
28.1 |
2.4 |
7 |
<ems>T4-“pleural dissemination” (IASLC [rarrow] M1a) |
467 |
425 |
20.4 |
2.6 |
4 |
<ems>T4-“pericardial effusion” (IASLC [rarrow] M1a) |
82 |
69 |
24.3 |
—b |
3.5 |
<ems>M-“distant metastasis” (IASLC [rarrow] M1b) |
2181 |
1985 |
16.2 |
1.0 |
4 |
<<tabft>>aData suppressed due to no events after 24 mo.
<mc>bData suppressed due to no events after 24 mo.</.>
<<tt>>TABLE 4.
<mc>Comparison of Survival Characteristics of the CCR Validation Dataset versus the IASLC SEER Validation Set
|
CCR validation set |
IASLC SEER validation set |
||
1-yr survival estimate (%) |
Median overall survival (mo) |
1-yr survival estimate (%) |
Median overall survival (mo) |
|
T4-“additional nodule in same lobe” (IASLC T3) |
64.0 |
20 |
59a |
— |
“Ipsilateral Intra-pulmonary nodules” (IASLC T4) |
46.2 |
11 |
47a |
11a |
T4-“invasion” (IASLC T4) |
47.4 |
12 |
40b |
10b |
“Contralateral intra-pulmonary nodules” (IASLC M1a) |
31.1 |
7 |
31b |
6b |
“Pleural dissemination” (IASLC M1a) |
22.7 |
5 |
21b |
4b |
“Distant Metastasis” (IASLC M1b) |
18.3 |
4 |
15b |
3b |
<<tabft>>aData from Groome PA, Bolejack V, Crowley JJ, et al. The IASLC lung cancer staging project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage grouping in the forth coming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2007;2:694–705.
<mc>bData from Postmus PE, Brambilla E, Chansky K, et al. The IASLC lung cancer staging project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. J Thorac Oncol 2007;2:686–693.</.>
<<tt>>TABLE 5.
<mc>Overall Survival of non-BAC NSCLC Patients with “IASLC T4”, Pleural Dissemination and Pericardial Effusion without Distant Metastasis According to Nodal Status
Nodal status |
Total |
Deaths |
1-yr survival estimate (%) |
5-yr survival estimate (%) |
Median OS (mo) |
p |
“T4-invasion” (IASLC proposed T4) (N = 1301) |
||||||
<ems>N0 |
362 |
246 |
54.3 |
14.8 |
14 |
[lt] 0.0001 |
<ems>N1 |
126 |
88 |
58.8 |
11.3 |
16 |
|
<ems>N2 |
707 |
539 |
43.6 |
9.8 |
11 |
|
<ems>N3 |
106 |
88 |
36.5 |
6.1 |
9 |
|
Malignant pleural dissemination (IASLC proposed M1a) (N = 1773) |
||||||
<ems>N0 |
480 |
398 |
32.1 |
6.2 |
6 |
[lt] 0.0001 |
<ems>N1 |
73 |
63 |
31.6 |
7.4 |
6 |
|
<ems>N2 |
1050 |
945 |
18.3 |
2.4 |
4 |
|
<ems>N3 |
170 |
151 |
20.0 |
4.9 |
5 |
|
Malignant pericardial effusion (IASLC proposed M1a) (N = 320) |
||||||
<ems>N0 |
33 |
26 |
32.5 |
7.0 |
5 |
0.0461 |
<ems>N1 |
7 |
5 |
28.6 |
—a |
7 |
|
<ems>N2 |
206 |
187 |
13.8 |
2.1 |
3 |
|
<ems>N3 |
74 |
64 |
21.8 |
4.0 |
5 |
<<tabft>>aData suppressed due to insufficient events after 10 mo.</.>
<<tt>>TABLE 6.
<mc>Pairwise Comparison of Hazards Ratio (HR) of Death between Pericardial Effusion and Other IASLC M Descriptors
Pairwise comparison |
HR |
95% Confidence Interval |
p |
Malignant pericardial effusion vs. contralateral intra-pulmonary nodules |
1.453 |
1.271–1.660 |
[lt] 0.0001 |
Malignant pericardial effusion vs. malignant pleural dissemination |
1.146 |
1.010–1.302 |
0.0379 |
Malignant pericardial effusion vs. distant metastasis (IASLC M1b) |
1.032 |
0.916–1.163 |
0.6090 |
<<tabft>></.>
<<tt>>TABLE 7.
<mc>Reclassifications of All Patients from the UICC6 Stage Grouping to IASLC Stage Grouping
UICC6 stage grouping (total) |
IASLC stage grouping (total) |
|||||||
IA (3000) |
IB (2573) |
IIA (1509) |
IIB (1037) |
IIIA (3660) |
IIIB (1677) |
IVA (3241)a |
IVB (6886)a |
|
IA (3000) |
3000 |
— |
— |
— |
— |
— |
— |
— |
IB (3430) |
— |
2573 |
608 |
249 |
— |
— |
— |
— |
IIA (338) |
— |
— |
338 |
— |
— |
— |
— |
— |
IIB (1383) |
— |
— |
563 |
607 |
213 |
— |
— |
— |
IIIA (2531) |
— |
— |
— |
— |
2460 |
71 |
— |
— |
IIIB (4122) |
— |
— |
— |
181 |
698 |
1150 |
2093 |
— |
IV (8779) |
— |
— |
— |
— |
289 |
456 |
1148 |
6886 |
<<tabft>></.>
<<tt>>TABLE 8.
<mc>Comparison of Overall Survival between UICC6 Staging and IASLC Proposed Staging by Various Stages
UICC6 |
IASLC |
||||||||||
Stage |
Total (%) |
Deaths |
1-yr survival estimate (%) |
5-yr survival estimate (%) |
Median Overall survival (mo) |
Stage |
Total (%) |
Deaths |
1-yr survival estimate (%) |
5-yr survival estimate (%) |
Median Overall survival (mo) |
Stage IA |
3000 (12.7%) |
889 |
87.9 |
52.0 |
NR |
Stage IA |
3000 (12.7%) |
889 |
87.9 |
52.0 |
NR |
Stage IB |
3430 (14.5%) |
1370 |
79.4 |
42.0 |
45 |
Stage IB |
2573 (10.9%) |
968 |
82.0 |
44.1 |
50 |
Stage IIA |
338 (1.4%) |
143 |
84.4 |
38.2 |
41 |
Stage IIA |
1509 (6.4%) |
718 |
76.1 |
32.6 |
35 |
Stage IIB |
1383 (5.9%) |
771 |
68.5 |
26.5 |
25 |
Stage IIB |
1037 (4.4%) |
556 |
68.4 |
29.3 |
25 |
Stage IIIA |
2531 (10.7%) |
1704 |
58.4 |
14.4 |
15 |
Stage IIIA |
3660 (15.5%) |
2424 |
58.8 |
15.9 |
16 |
Stage IIIB |
4122 (17.5%) |
3267 |
36.3 |
8.7 |
8 |
Stage IIIB |
1677 (7.1%) |
1305 |
41.4 |
8.1 |
10 |
Stage V |
8779 (37.2%) |
7756 |
22.4 |
2.4 |
5 |
Stage IVAa |
3241 (13.7%) |
2788 |
25.2 |
4.1 |
6 |
|
|
|
|
|
|
Stage IVBa |
6886 (29.2%) |
6252 |
18.3 |
1.3 |
4 |
<<tabft>>aThere is no official stage IVA (M1a) or stage IVB (M1b) as currently proposed by IASLC.
<mc>NR, not reached.</.>
<<tt>>TABLE 9.
<mc>Comparison of Median Overall of Advanced Stage non-BAC NSCLC between CCR Validation Set and IASLC SEER Validation Set
|
Median overall survival (mo) |
|||
CCR validation set |
IASLC SEER validation set |
|||
UICC6 |
IASLC |
UICC6 |
IASLC |
|
Stage IIIA |
15 |
16 |
14a |
14a |
Stage IIIB |
8 |
10 |
8a |
9a |
Stage IV |
5 |
— |
4a |
4a |
Stage IVAb |
|
6 |
|
|
Stage IVBb |
|
4 |
|
|
<<tabft>>aData from Groome PA, Bolejack V, Crowley JJ, et al. The IASLC lung cancer staging project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage grouping in the forth coming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2007;2:694–705.
<mc>bThere is no official stage IVA (M1a) and stage IVB (M1b) as proposed by IASLC.</.>
<<tt>>TABLE 10.
<mc>Pairwise Comparisons of Hazard Ratio of UICC and IASLC Stages
Comparisons |
Hazard ratio |
p |
||
UICC6 |
IASLC |
UICC6 |
IASLC |
|
IB vs. IA |
1.465 (1.347–1.594) |
1.337 (1.221–1.465) |
[lt] 0.0001 |
[lt] 0.0001 |
IIA vs. IB |
0.996 (0.838–1.183) |
1.369 (1.243–1.508) |
0.9612 |
[lt] 0.0001 |
IIB vs. IIA |
1.639 (1.371–1.960) |
1.267 (1.134–1.415) |
[lt] 0.0001 |
[lt] 0.0001 |
IIIA vs. IIB |
1.481 (1.360–1.613) |
1.467 (1.338–1.609) |
[lt] 0.0001 |
[lt] 0.0001 |
IIIB vs. IIIA |
1.623 (1.530–1.721) |
1.516 (1.417–1.622) |
[lt] 0.0001 |
[lt] 0.0001 |
IV vs. IIIB |
1.461 (1.403–1.523) |
1.770 (1.669–1.876) |
[lt] 0.0001 |
[lt] 0.0001 |
<<tabft>></.>
<<tt>>TABLE 11.
<mc>Comparison of Hazards Ratio of Stage According to UICC6 and IASLC Proposed Staging System Using Cox Proportional Hazards Regression Analysis
UICC6 |
IASLC |
||||||
Stage |
Hazards ratioa |
95% confidence interval |
p |
Stage |
Hazards ratioa |
95% confidence interval |
p |
Stage IA |
1.00 |
|
|
Stage IA |
1.00 |
|
|
Stage IB |
1.414 |
(1.300–1.539) |
[lt] 0.0001 |
Stage IB |
1.301 |
(1.188–1.426) |
[lt] 0.0001 |
Stage IIA |
1.607 |
(1.347–1.918) |
[lt] 0.0001 |
Stage IIA |
1.908 |
(1.729–2.107) |
[lt] 0.0001 |
Stage IIB |
2.525 |
(2.291–2.784) |
[lt] 0.0001 |
Stage IIB |
2.360 |
(2.120–2.626) |
[lt] 0.0001 |
Stage IIIA |
2.798 |
(2.566–3.050) |
[lt] 0.0001 |
Stage IIIA |
3.004 |
(2.767–3.261) |
[lt] 0.0001 |
Stage IIIB |
3.686 |
(3.396–4.002) |
[lt] 0.0001 |
Stage IIIB |
3.681 |
(3.346–4.048) |
[lt] 0.0001 |
Stage IV |
5.246 |
(4.844–5.682) |
[lt] 0.0001 |
Stage IVAb |
4.897 |
(4.493–5.338) |
[lt] 0.0001 |
|
|
|
|
Stage IVBb |
6.842 |
(6.296–7.436) |
[lt] 0.0001 |
<<tabft>>aAdjusted for age, gender, ethnicity, socioeconomic status, histology, histologic grade, surgery, radiation, and chemotherapy.
<mc>bThere is no official stage IVA (M1a) or stage IVB (M1b) as currently proposed by IASLC.</.>
<<tt>>SUPPLEMENTAL TABLE 1.
<mc>Cox Multivariate Analysis of the UICC6 Staging System
|
Hazards ratio |
95% confidence interval |
p |
Stage |
|||
<ems>Stage IA |
1.000 |
|
|
<ems>Stage IB |
1.414 |
(1.300–1.539) |
[lt] 0.0001 |
<ems>Stage IIA |
1.607 |
(1.347–1.918) |
[lt] 0.0001 |
<ems>Stage IIB |
2.525 |
(2.291–2.784) |
[lt] 0.0001 |
<ems>Stage IIIA |
2.798 |
(2.566–3.050) |
[lt] 0.0001 |
<ems>Stage IIIB |
3.686 |
(3.396–4.002) |
[lt] 0.0001 |
<ems>Stage IV |
5.246 |
(4.844–5.682) |
[lt] 0.0001 |
Age |
1.010 |
(1.008–1.011) |
[lt] 0.0001 |
Gender |
|||
<ems>Male |
1.000 |
|
[lt] 0.0001 |
<ems>Female |
0.858 |
(0.831–0.886) |
|
Ethnicity |
|||
<ems>Caucasian |
1.000 |
|
|
<ems>African-American |
0.990 |
(0.933–1.050) |
0.7360 |
<ems>Hispanic |
0.954 |
(0.902–1.008) |
0.0956 |
<ems>Chinese |
0.774 |
(0.698–0.859) |
[lt] 0.0001 |
<ems>Non-Chinese Asian |
0.888 |
(0.831–0.948) |
0.0004 |
<ems>Other |
1.032 |
(0.802–1.328) |
0.8040 |
Histology |
|||
<ems>Adenocarcinoma |
1.000 |
|
|
<ems>Squamous cell carcinoma |
1.059 |
(1.019–1.101) |
0.0036 |
<ems>Large cell carcinoma |
1.120 |
(1.040–1.207) |
0.0027 |
<ems>Undifferentiated |
1.062 |
(1.024–1.101) |
0.0012 |
Histologic grade |
|||
<ems>Well-differentiated |
1.000 |
|
|
<ems>Moderately-differentiated |
1.217 |
(1.105–1.341) |
[lt] 0.0001 |
<ems>Poorly-differentiated |
1.350 |
(1.230–1.482) |
[lt] 0.0001 |
<ems>Undifferentiated |
1.463 |
(1.296–1.650) |
[lt] 0.0001 |
<ems>Unknown |
1.257 |
(1.143–1.382) |
[lt] 0.0001 |
Socioeconomic status |
|||
<ems>Quintile 1 (SES1-lowest) |
1.000 |
|
|
<ems>Quintile 2 (SES2) |
0.914 |
(0.867–0.963) |
0.0008 |
<ems>Quintile 3 (SES3) |
0.878 |
(0.834–0.925) |
[lt] 0.0001 |
<ems>Quintile 4 (SES4) |
0.836 |
(0.793–0.881) |
[lt] 0.0001 |
<ems>Quintile 5 (SES5-highest) |
0.809 |
(0.766–0.854) |
[lt] 0.0001 |
Surgery |
|||
<ems>No |
1.000 |
|
[lt] 0.0001 |
<ems>Yes |
0.317 |
(0.301–0.334) |
|
Radiation |
|||
<ems>No |
1.000 |
|
[lt] 0.0001 |
<ems>Yes |
0.883 |
(0.854–0.914) |
|
Chemotherapy |
|||
<ems>No |
1.000 |
|
|
<ems>Yes |
0.556 |
(0.536–0.577) |
[lt] 0.0001 |
<ems>Unknown |
0.804 |
(0.732–0.884) |
[lt] 0.0001 |
<<tabft>></.>
<<tt>>SUPPLEMENTAL TABLE 2.
<mc>Cox Multivariate Analysis of the IASLC Proposed Staging System
|
Hazards ratio |
95% confidence interval |
p |
Stage |
|||
<ems>Stage IA |
1.000 |
|
|
<ems>Stage IB |
1.301 |
(1.188–1.426) |
[lt] 0.0001 |
<ems>Stage IIA |
1.908 |
(1.729–2.107) |
[lt] 0.0001 |
<ems>Stage IIB |
2.360 |
(2.120–2.626) |
[lt] 0.0001 |
<ems>Stage IIIA |
3.004 |
(2.767–3.261) |
[lt] 0.0001 |
<ems>Stage IIIB |
3.681 |
(3.346–4.048) |
[lt] 0.0001 |
<ems>Stage IVAa |
4.897 |
(4.493–5.338) |
[lt] 0.0001 |
<ems>Stage IVBa |
6.842 |
(6.296–7.436) |
[lt] 0.0001 |
Age |
1.011 |
(1.010–1.013) |
[lt] 0.0001 |
Gender |
|||
<ems>Male |
1.000 |
|
[lt] 0.0001 |
<ems>Female |
0.866 |
(0.839–0.895) |
|
Ethnicity |
|||
<ems>Caucasian |
1.000 |
|
|
<ems>African-American |
0.992 |
(0.936–1.052) |
0.7940 |
<ems>Hispanic |
0.945 |
(0.894–1.000) |
0.0486 |
<ems>Chinese |
0.762 |
(0.687–0.845) |
[lt] 0.0001 |
<ems>Non-Chinese Asian |
0.891 |
(0.834–0.952) |
0.0006 |
<ems>Other |
1.033 |
(0.803–1.329) |
0.8016 |
Histology |
|||
<ems>Adenocarcinoma |
1.000 |
|
|
<ems>Squamous cell carcinoma |
1.086 |
(1.045–1.129) |
[lt] 0.0001 |
<ems>Large cell carcinoma |
1.119 |
(1.039–1.206) |
0.0031 |
<ems>Undifferentiated |
1.063 |
(1.025–1.102) |
0.0010 |
Histologic grade |
|||
<ems>Well-differentiated |
1.000 |
|
|
<ems>Moderately-differentiated |
1.174 |
(1.065–1.294) |
0.0012 |
<ems>Poorly-differentiated |
1.289 |
(1.175–1.415) |
[lt] 0.0001 |
<ems>Undifferentiated |
1.375 |
(1.219–1.552) |
[lt] 0.0001 |
<ems>Unknown |
1.183 |
(1.076–1.301) |
0.0005 |
Socioeconomic status |
|||
<ems>Quintile 1 (SES1-lowest) |
1.000 |
|
|
<ems>Quintile 2 (SES2) |
0.912 |
(0.866–0.961) |
0.0006 |
<ems>Quintile 3 (SES3) |
0.882 |
(0.838–0.929) |
[lt] 0.0001 |
<ems>Quintile 4 (SES4) |
0.831 |
(0.788–0.877) |
[lt] 0.0001 |
<ems>Quintile 5 (SES5-highest) |
0.808 |
(0.765–0.853) |
[lt] 0.0001 |
Surgery |
|||
<ems>No |
1.000 |
|
[lt] 0.0001 |
<ems>Yes |
0.356 |
(0.337–0.375) |
|
Radiation |
|||
<ems>No |
1.000 |
|
[lt] 0.0001 |
<ems>Yes |
0.869 |
(0.840–0.899) |
|
Chemotherapy |
|||
<ems>No |
1.000 |
|
|
<ems>Yes |
0.556 |
(0.536–0.577) |
[lt] 0.0001 |
<ems>Unknown |
0.812 |
(0.739–0.892) |
[lt] 0.0001 |
<<tabft>>aThere is no official stage IVA (M1a) and stage IVB (M1b) as proposed by IASLC.</.>